The following is a summary of the Getinge AB (GNGBF) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Getinge reported Q1 2024 sales increase by 5.2% and order intake growth by 7.8%, with organic order growth being 2.5%.

• The adjusted EBITDA margin was lower than the prior year due to higher costs, despite the sales increase.

• Getinge's strong free cash flow and a solid financial position will enable continued investment in profitable growth.

• Revenue increased further following the successful acquisitions of Healthmark and High Purity New England, which performed beyond company expectations.

• The revenue increment was partly offset by quality challenges, affecting supply chains.

Business Progress:

• Several new products including the Hemopro 3, Servo TwinView, and the Aquadis Index were launched.

• Significant strides in sustainability efforts, with CO2 emissions continuing to trend positively.

• Ongoing quality improvement efforts in Cardiac Assist and Cardiopulmonary.

• Forecasting an organic net sales growth in the 2% to 5% range for 2024.

• Surgical Workflows business experienced growth, which is expected to continue.

• Signed a distribution agreement with Cook for the covered stents, indicating potential strength in the Critical Care business.

• Increased capital expenditure expected due to increased investment in future portfolios and quality improvement areas. A detailed update on end market growth, cost evolution, and business mix to be provided on May 15th.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.